George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEco Animal Regulatory News (EAH)

Share Price Information for Eco Animal (EAH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 107.50
Bid: 105.00
Ask: 110.00
Change: 5.00 (4.88%)
Spread: 5.00 (4.762%)
Open: 102.50
High: 107.50
Low: 102.50
Prev. Close: 102.50
EAH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Statement re Joint poultry vaccine development licencing deal

19 Nov 2018 07:00

ECO Animal Health Group plc

(AIM: EAH)

ECO Animal Health and University of Georgia sign poultry vaccine development licencing deal

ECO Animal Health Ltd (ECO), a wholly owned subsidiary of ECO Animal Health Group plc, is pleased to announce that it has entered into a licensing deal with the Poultry Diagnostic & Research Center, College of Veterinary Medicine at the University of Georgia (UGA).

This deal, at a cost of just over $1 million in phased payments of eight quarterly instalments over a two year period, allows ECO to license research related innovations leading to the development of potential vaccines in the field of Mycoplasma gallisepticum, a bacterium that can cause severe respiratory disease in poultry. A joint steering committee will meet monthly to review data, monitor progress and reach go/no-go decisions.

Peter Lawrence, Chairman of ECO Animal Health Group plc said, “Mycoplasma-related illnesses in poultry can be financially devastating to commercial poultry producers with global losses estimated at more than £500 million annually. We are delighted to have entered into this collaboration with UGA and expect that further innovative developments will follow”.

Professor Naola Ferguson-Noel, a researcher in the Poultry Diagnostic & Research Center said, “Although Mycoplasma control programs are often based on biosecurity, early detection, quarantine and elimination of positive flocks, vaccination can be a very effective option in some circumstances. I do think a vaccine is within reach.”

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

Contacts:

ECO Animal Health Group plc

Peter Lawrence 020 8336 6190
Marc Loomes 020 8447 6906
Spiro Financial
Anthony Spiro 020 8336 6196
N+1 Singer (Nominated Adviser) 020 7496 3000
Mark Taylor, Brough Ransom
Peel Hunt LLP (Joint Broker)
James Steel, Dr Christopher Golden 020 7418 8900

-----------------------------------------------------

About ECO Animal Health Ltd

ECO Animal Health based in London U.K. is a leader in the development, registration and marketing of pharmaceutical products for global animal health markets. Its products for these growth markets promote well-being in animals and include the novel antimicrobial, Aivlosin®, as well as a range of generic therapeutic products.

About University of Georgia

UGA is an American public, flagship, and comprehensive research university based in Athens, Georgia. It has been ranked in the Top 10 of all USA universities for licensing deals for the past decade and, to date, more than 700 UGA products and technologies have been introduced to the marketplace.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181118005025/en/

Copyright Business Wire 2018

Date   Source Headline
25th Apr 20247:00 amRNSTrading Update on year ended 31 March 2024
8th Apr 20247:00 amRNSHolding(s) in Company
4th Apr 20247:00 amRNSDisposal of non-core product line
22nd Mar 20247:00 amRNSShare Awards to Executive Directors
21st Mar 20249:13 amRNSReplacement: Trading Update
21st Mar 20247:00 amRNSTrading Update
19th Mar 20249:40 amRNSGeneral Meeting Result
27th Feb 20247:00 amRNSPublication of Notice of General Meeting
6th Feb 20247:00 amRNSTrademark Approval for ECOVAXXIN® family in the EU
8th Jan 20247:00 amRNSDisposal of Freehold Properties
5th Jan 20245:05 pmRNSHolding(s) in Company
5th Jan 20245:00 pmRNSHolding(s) in Company
22nd Dec 20237:00 amRNSDeferred Option Awards to Executive Directors
1st Dec 20237:00 amRNSDirector/PDMR Shareholding
27th Nov 202310:00 amRNSInvestor Presentation
27th Nov 20237:00 amRNSResults for the six months ended 30 September 2023
14th Nov 20233:00 pmRNSHolding(s) in Company
9th Nov 20237:00 amRNSCapital Markets Day Events
24th Oct 20237:00 amRNSNew USA and Canada label claim for Aivlosin®
28th Sep 20237:00 amRNSESG Rating
7th Sep 20232:57 pmRNSResult of AGM
10th Aug 20237:00 amRNSNotice of AGM
21st Jul 20234:25 pmRNSPosting of the Annual Report and Accounts
10th Jul 20237:00 amRNSFinal Results for the Year Ended 31 March 2023
5th Jul 20237:00 amRNSNotice of Results & Investor Presentation
6th Jun 20237:00 amRNSIssue of Equity and Total Voting Rights
18th May 20237:00 amRNSHolding(s) in Company
23rd Mar 20237:00 amRNSTrading Update
8th Mar 20237:00 amRNSAnimal Health Innovation Summit
27th Feb 202310:37 amRNSDirector/PDMR Shareholding
24th Feb 20233:19 pmRNSChange of Registered Address
17th Feb 20231:41 pmRNSHolding(s) in Company
13th Feb 20231:55 pmRNSHolding(s) in Company
9th Feb 20237:00 amRNSHolding(s) in Company
9th Feb 20237:00 amRNSHolding(s) in Company
8th Feb 20237:00 amRNSDirector/PDMR Shareholding
20th Jan 202312:14 pmRNSHolding(s) in Company
13th Dec 20223:50 pmRNSDeferred Share Option Awards
30th Nov 20223:01 pmRNSDirector/PDMR Shareholding
25th Nov 20221:37 pmRNSDirector/PDMR Shareholding
23rd Nov 20227:00 amRNSResults for the six months ended 30 September 2022
22nd Nov 20227:00 amRNSInvestor Presentation covering Interim Results
14th Nov 20227:00 amRNSChange of Auditor
31st Oct 20227:00 amRNSBlock listing Interim Review
24th Oct 20221:30 pmRNSHolding(s) in Company
24th Oct 20221:28 pmRNSHolding(s) in Company
26th Sep 20224:01 pmRNSResult of AGM
5th Sep 20221:00 pmRNSInvestor Presentation covering Full Year Results
2nd Sep 20227:00 amRNSPublication of Annual Report and Notice of AGM
31st Aug 20227:00 amRNSFinal Results for the Year Ended 31 March 2022

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.